{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:58:23Z","timestamp":1791302303944,"version":"4.1.0"},"reference-count":25,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Traditional management of relapsed or refractory (R\/R) marginal zone lymphoma (MZL) comprises chemotherapy, rituximab or rituximab-based chemoimmunotherapy (CIT). Zanubrutinib, a Bruton tyrosine kinase inhibitor, has shown high overall response rates and durable responses across MZL subtypes in two Phase II, single-arm trials. As no head-to-head randomized study exists, an unanchored matching-adjusted indirect comparison was performed to estimate the relative efficacy of zanubrutinib versus traditional agents.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    Pooled patient-level data for 86 evaluable patients from zanubrutinib trials were compared with aggregate-level data from 90 patients treated with chemotherapy, rituximab or CIT in the Haematological Malignancy Research Network registry. Logistic propensity score models were used to match the populations for key characteristics. Progression-free survival (PFS) and overall survival (OS) associated with each treatment were estimated from Cox models. Since patients receiving chemotherapy generally have less favorable outcomes, a sensitivity analysis comparing zanubrutinib against CIT or rituximab alone was performed. Leave-one-out analyses were conducted where one covariate at a time was omitted to explore its impact on the results.\n                    <jats:bold>Results:<\/jats:bold>\n                    The effective sample size for zanubrutinib after matching was 38. Compared with chemotherapy, rituximab or CIT, zanubrutinib significantly increased PFS (hazard ratio [HR]: 0.30 [95% CI: 0.15\u20130.63]; p\u00a0=\u00a00.001) and OS (HR: 0.23 [95% CI: 0.10\u20130.50]; p\u00a0&lt;\u00a00.001) in patients with R\/R MZL. Findings were consistent across leave-one-out analyses and when excluding patients who received chemotherapy only.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Modeling using clinical trial and real-world data from an unanchored matching-adjusted indirect comparison suggests that zanubrutinib was associated with longer PFS and OS compared with chemotherapy, rituximab or CIT in patients with R\/R MZL.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0132","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:23:50Z","timestamp":1791300230000},"source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma"],"prefix":"10.57264","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5693-2789","authenticated-orcid":false,"given":"Renata","family":"Walewska","sequence":"first","affiliation":[{"name":"Cancer Care, University Hospitals Dorset, Bournemouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Wang","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd., San Carlos, CA 94070, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Smare","sequence":"additional","affiliation":[{"name":"Precision AQ, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Precision AQ, Oakland, CA 94612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvy","family":"Mardiguian","sequence":"additional","affiliation":[{"name":"BeOne Medicines Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[{"name":"Precision AQ, Vancouver, BC V6H 3Y4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M","family":"Linton","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust &amp; Division of Cancer Sciences, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet S","family":"Walter","sequence":"additional","affiliation":[{"name":"Leicester Cancer Research Centre, University of Leicester &amp; University Hospitals Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/asheducation-2008.1.359","article-title":"Marginal zone lymphomas: management of nodal, splenic, and MALT NHL","volume":"2008","author":"Kahl B","year":"2008","unstructured":"Kahl B, Yang D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Hematology Am. Soc. Hematol. Educ. Program 2008(1), 359\u2013364 (2008).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.021908.132607","article-title":"Human marginal zone B cells","volume":"27","author":"Weill J-C","year":"2009","unstructured":"Weill J-C, Weller S, Reynaud C-A. Human marginal zone B cells. Ann. Rev. Immunol. 27, 267\u2013285 (2009).","journal-title":"Ann. Rev. Immunol."},{"issue":"1","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca E","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(1), 17\u201329 (2020).","journal-title":"Ann. Oncol."},{"key":"e_1_3_8_6_2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NLet al. (Eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, France (2017)."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.19064","article-title":"Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline","volume":"204","author":"Walewska R","year":"2024","unstructured":"Walewska R, Eyre TA, Barrington S Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br. J. Haematol. 204(1), 86\u2013107 (2024).","journal-title":"Br. J. Haematol."},{"issue":"11","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines","volume":"21","author":"Zelenetz AD","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023: Featured Updates to the NCCN Guidelines. J. Natl Compr. Canc. Netw. 21(11), 1118\u20131131 (2023).","journal-title":"J. Natl Compr. Canc. Netw."},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/hematology.2022000362","article-title":"Management of marginal zone lymphomas","volume":"2022","author":"Merli M","year":"2022","unstructured":"Merli M, Arcaini L. Management of marginal zone lymphomas. Hematology 2022(1), 676\u2013687 (2022).","journal-title":"Hematology"},{"issue":"1","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/asheducation.V2012.1.426.3798535","article-title":"The many faces of marginal zone lymphoma","volume":"2012","author":"Zinzani PL","year":"2012","unstructured":"Zinzani PL. The many faces of marginal zone lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2012(1), 426\u2013432 (2012).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal zone lymphoma: state-of-the-art treatment","volume":"20","author":"Sindel A","year":"2019","unstructured":"Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: state-of-the-art treatment. Curr. Treat. Options Oncol. 20, 1\u201315 (2019).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"3","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara C","year":"2020","unstructured":"McNamara C, Montoto S, Eyre TA The investigation and management of follicular lymphoma. Br. J. Haematol. 191(3), 363\u2013381 (2020).","journal-title":"Br. J. Haematol."},{"issue":"5","key":"e_1_3_8_13_2","first-page":"28","article-title":"Current treatment options in marginal zone lymphoma","volume":"13","author":"Roberts M","year":"2017","unstructured":"Roberts M, Tripathy D, Martin P. Current treatment options in marginal zone lymphoma. Am. J. Hematology\/Oncology 13(5), 28\u201333 (2017).","journal-title":"Am. J. Hematology\/Oncology"},{"issue":"17","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis TA","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135\u20133143 (2000).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat S","year":"2021","unstructured":"Opat S, Tedeschi A, Linton K The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin. Cancer Res. 27(23), 6323\u20136332 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/bloodadvances.2021006083","article-title":"Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"6","author":"Phillips T","year":"2022","unstructured":"Phillips T, Chan H, Tam CS Zanubrutinib monotherapy in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood Adv. 6(11), 3472\u20133479 (2022).","journal-title":"Blood Adv."},{"key":"e_1_3_8_17_2","unstructured":"NICE. Guide to the methods of technology appraisal 2013. The reference case. (2013). (Accessed 24 March 2024). https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case"},{"issue":"27","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. J. Clin. Oncol. 32(27), 3059\u20133067 (2014).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_8_19_2","unstructured":"HMRN. The Clinical management and outcome of marginal zone lymphoma (MZL) with a focus on relapsed\/refractory disease: a report from the Haematological Malignancy Research Network 2024. Updated: 24 February 2024. https:\/\/hmrn.org\/publications\/reports"},{"key":"e_1_3_8_20_2","unstructured":"Phillippo DM Ades AE Dias S NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE. (2016). https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/full-list"},{"issue":"3","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch PM","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81(3), 515\u2013526 (1994).","journal-title":"Biometrika"},{"issue":"1","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/biomet\/77.1.147","article-title":"Martingale-based residuals for survival models","volume":"77","author":"Therneau TM","year":"1990","unstructured":"Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 77(1), 147\u2013160 (1990).","journal-title":"Biometrika"},{"issue":"14","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard J","year":"2019","unstructured":"Leonard J, Trneny M, Izutsu K ; AUGMENT trial investigators. AUGMENT: a Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J. Clin. Oncol. 37(14), 1188\u20131199 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, Phase III trial","volume":"22","author":"Matasar MJ","year":"2021","unstructured":"Matasar MJ, Capra M, \u00d6zcan M Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, Phase III trial. Lancet Oncol. 22(5), 678\u2013689 (2021).","journal-title":"Lancet Oncol."},{"issue":"16","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"e19526","DOI":"10.1200\/JCO.2023.41.16_suppl.e19526","article-title":"Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)","volume":"41","author":"Thieblemont C","year":"2023","unstructured":"Thieblemont C, Wang K, Keeping S Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC). J. Clin. Oncol. 41(Suppl. 16), e19526 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam CS","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 6(4), 1296\u20131308 (2022).","journal-title":"Blood Adv."},{"issue":"7","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3324\/haematol.2023.283846","article-title":"Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database","volume":"109","author":"Brown JR","year":"2024","unstructured":"Brown JR, Ghia P, Jurczak W Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database. Haematologica 109(7), 2277\u20132283 (2024).","journal-title":"Haematologica"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:23:54Z","timestamp":1791300234000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":25,"alternative-id":["10.57264\/cer-2026-0132"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0132","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"e260132"}}